Skip to main content
SpringerLink
Log in

Patienten mit ossär metastasiertem Prostatakarzinom: Können Bisphosphonate helfen?

Patients with prostate cancer bone metastases: can bisphosphonates help?

  • Evidenzbasierte Medizin
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abetz L, Barghout V, Arbuckle R, Bosch V, Shirina N, Saad F (2006) Impact of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases in a randomised placebocontrol trial. J Clin Oncol. http://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.4638

  2. Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC et al (2017) Bone health and bonetargeted therapies for prostate cancer: a programme in evidence-based care—cancer care ontario clinical practice guideline. Clin Oncol 29(6):348–355

    Article  CAS  Google Scholar 

  3. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31(5):578–583

    Article  CAS  Google Scholar 

  4. Coleman R, Gnant M, Morgan G, Clezardin P (2012) Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 104(14):1059–1067

    Article  CAS  Google Scholar 

  5. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8 Suppl):1588–1594

    Article  CAS  Google Scholar 

  6. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642

    Article  Google Scholar 

  7. Elomaa I, Kylmata T, Tammela T, Vitanen J, Ottelin M, Ruutu K et al (1992) Effect of oral clodronate on bone pain: a controlled study in patients with metastatic prostate cancer. Int J Urol Nephrol 24(2):159–166

    Article  CAS  Google Scholar 

  8. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ et al (2003) Randomized, double-blind, controlled trial of mitoxantron/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21(17):3335–3342

    Article  CAS  Google Scholar 

  9. Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P et al (2015) Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol 68(1):42–50

    Article  Google Scholar 

  10. James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I et al (2016) TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technol Assess (Rockv) 20(53):1–127

    Article  Google Scholar 

  11. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163–1177

    Article  CAS  Google Scholar 

  12. Kylmala T, Tammela T, Risteli L, Risteli J, Taube T, Elomma I (1993) Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 29A(6):821–825

    Article  CAS  Google Scholar 

  13. Kylmala T, Taube T, Tammela TL (1997) Concomitant i. v. and oral clodronate in the relief of bone pain: a double-blind placebo-controlled study in patients with metastatic prostate cancer. Br J Cancer 76:939–942

    Article  CAS  Google Scholar 

  14. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2018) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.0, AWMF Registernummer: 043/022OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/. Zugegriffen: 18. Jan. 2019

    Google Scholar 

  15. Macherey S, Monsef I, Jahn F, Jordan K, Yuen KK, Heidenreich A, Skoetz N (2017) Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006250.pub2

    Article  PubMed  Google Scholar 

  16. Meulenbeld HJ, van Werkhoven ED, Coenen JLLM, Creemers GJ, Loosveld OJL, de Jong PC et al (2012) Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). Eur J Cancer 48:2993–3000

    Article  CAS  Google Scholar 

  17. Saad F, Eastham J (2010) Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 76:1175–1181

    Article  Google Scholar 

  18. Small EJ, Matthew RS, Seaman JJ, Petrone S, Kowalski MO (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostatic cancer. J Clin Oncol 21(23):4277–4284

    Article  CAS  Google Scholar 

  19. Smith JA Jr. (1989) Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 141:85–87

    Article  Google Scholar 

  20. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W et al (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143–1150

    Article  CAS  Google Scholar 

  21. Strang P, Nilsson S, Brandstedt S (1997) The analgesic efficacy of clodronate compared with placebo inpatients with painful bone metastases from prostatic cancer. Anticancer Res 17:4717–4721

    CAS  PubMed  Google Scholar 

Download references

Danksagung

UroEvidence dankt Claudia Bollig und Katharina Kohler (beide Cochrane Deutschland Stiftung) für die Durchsicht und Kommentare zu dieser Übersetzung.

Author information

Authors and Affiliations

  1. UroEvidence, Nestorstraße 8–9 (1. Hof), 10709, Berlin, Deutschland

    Laura-Maria Krabbe

Authors
  1. Laura-Maria Krabbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura-Maria Krabbe.

Ethics declarations

Interessenkonflikt

L.-M. Krabbe gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krabbe, LM. Patienten mit ossär metastasiertem Prostatakarzinom: Können Bisphosphonate helfen?. Urologe 58, 314–318 (2019). https://doi.org/10.1007/s00120-019-0881-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-019-0881-x

Search

Navigation